tetano
Editor, Senior Moderator
Popul Health Manag
. 2023 Feb;26(1):29-36.
doi: 10.1089/pop.2022.0241.
Assessing Vulnerability to COVID-19 in High-Risk Populations: The Role of SARS-CoV-2 Spike-Targeted Serology
Harvey W Kaufman[SUP] 1 [/SUP], William A Meyer[SUP] 1 [/SUP], Nigel J Clarke[SUP] 1 [/SUP], Jeff Radcliff[SUP] 1 [/SUP], Christopher M Rank[SUP] 2 [/SUP], James Freeman[SUP] 3 [/SUP], Marcia Eisenberg[SUP] 4 [/SUP], Laura Gillim[SUP] 4 [/SUP], William G Morice[SUP] 5 [/SUP], David M Briscoe[SUP] 6 [/SUP], David S Perlin[SUP] 7 [/SUP], Jay G Wohlgemuth[SUP] 1 [/SUP]
Affiliations
Abstract
Individuals at increased risk for severe coronavirus disease-2019 (COVID-19) outcomes, due to compromised immunity or other risk factors, would benefit from objective measures of vulnerability to infection based on vaccination or prior infection. The authors reviewed published data to identify a specific role and interpretation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike-targeted serology testing. Specific recommendations are provided for an evidence-based and clinically-useful interpretation of SARS-CoV-2 spike-targeted serology to identify vulnerability to infection and potential subsequent adverse outcomes. Decreased vaccine effectiveness among immunocompromised individuals is linked to correspondingly high rates of breakthrough infections. Negative results on SARS-CoV-2 antibody tests are associated with increased risk for subsequent infection. "Low-positive" results on semiquantitative SARS-CoV-2 spike-targeted antibody tests may help identify persons at increased risk as well. Standardized SARS-CoV-2 spike-targeted antibody tests may provide objective information on the risk of SARS-CoV-2 infection and associated adverse outcomes. This holds especially for high-risk populations that demonstrate a relatively high rate of seronegativity. The widespread availability of such tests presents an opportunity to refine risk assessment for individuals with suboptimal SARS-CoV-2 antibody levels and to promote effective interventions. Interim federal guidance would support physicians and patients while additional investigations are pursued.
Keywords: COVID-19; SARS-CoV-2 antibody; immunocompromised; severe acute respiratory syndrome coronavirus 2; vaccination.
. 2023 Feb;26(1):29-36.
doi: 10.1089/pop.2022.0241.
Assessing Vulnerability to COVID-19 in High-Risk Populations: The Role of SARS-CoV-2 Spike-Targeted Serology
Harvey W Kaufman[SUP] 1 [/SUP], William A Meyer[SUP] 1 [/SUP], Nigel J Clarke[SUP] 1 [/SUP], Jeff Radcliff[SUP] 1 [/SUP], Christopher M Rank[SUP] 2 [/SUP], James Freeman[SUP] 3 [/SUP], Marcia Eisenberg[SUP] 4 [/SUP], Laura Gillim[SUP] 4 [/SUP], William G Morice[SUP] 5 [/SUP], David M Briscoe[SUP] 6 [/SUP], David S Perlin[SUP] 7 [/SUP], Jay G Wohlgemuth[SUP] 1 [/SUP]
Affiliations
- PMID: 36799932
- DOI: 10.1089/pop.2022.0241
Abstract
Individuals at increased risk for severe coronavirus disease-2019 (COVID-19) outcomes, due to compromised immunity or other risk factors, would benefit from objective measures of vulnerability to infection based on vaccination or prior infection. The authors reviewed published data to identify a specific role and interpretation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike-targeted serology testing. Specific recommendations are provided for an evidence-based and clinically-useful interpretation of SARS-CoV-2 spike-targeted serology to identify vulnerability to infection and potential subsequent adverse outcomes. Decreased vaccine effectiveness among immunocompromised individuals is linked to correspondingly high rates of breakthrough infections. Negative results on SARS-CoV-2 antibody tests are associated with increased risk for subsequent infection. "Low-positive" results on semiquantitative SARS-CoV-2 spike-targeted antibody tests may help identify persons at increased risk as well. Standardized SARS-CoV-2 spike-targeted antibody tests may provide objective information on the risk of SARS-CoV-2 infection and associated adverse outcomes. This holds especially for high-risk populations that demonstrate a relatively high rate of seronegativity. The widespread availability of such tests presents an opportunity to refine risk assessment for individuals with suboptimal SARS-CoV-2 antibody levels and to promote effective interventions. Interim federal guidance would support physicians and patients while additional investigations are pursued.
Keywords: COVID-19; SARS-CoV-2 antibody; immunocompromised; severe acute respiratory syndrome coronavirus 2; vaccination.